Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …

OBJECTIVE. Prophylactic vaccination of 16-to 23-year-old females with a quadrivalent
human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to …

CONTEXT: Each year, millions of US youth acquire sexually transmitted diseases (STDs).
Estimates of the economic burden of STDs can help to quantify the impact of STDs on the …

Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young
women (1106) were randomized to receive one of three formulations of a quadrivalent HPV …

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …

Syrjänen S. Current concepts on human papillomavirus infections in children. APMIS 2010;
118: 494–509. Current evidence is strong enough to conclude that human papillomavirus …

Human papillomavirus (HPV) is the most common sexually transmitted virus in the world.
About 70% of cervical cancers are caused by the most oncogenic HPV genotypes of 16 and …

Sexually transmitted diseases (STDs) are a major health problem for adolescents. Health
care providers for adolescents play a critical role in preventing and treating STDs. In May …

Objective: Administration of a quadrivalent HPV-6/11/16/18 vaccine to 16-to 26-year-old
women was highly effective in preventing HPV-6/11/16/18-related cervical/vulvar/vaginal …